Back to search

Article

Clinical Utility of the EpiSwitch CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the PROWES Study

2025-08-06

Abstract excerpt

<h4>Background: </h4> Immunotherapy has revolutionized oncology care, but clinical response to immune checkpoint inhibitors (ICIs) remains unpredictable, and treatment carries substantial risks and costs. The EpiSwitch® CiRT blood test is a novel 3D genomic assay that stratifies patients by probability of ICI benefit using a binary, blood-based classification: high (HPRR) or low (LPRR) probability of response. <h4...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
43174e1d-8281-58d5-8630-771c74f2d06c
DOI
10.20944/preprints202508.0023.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Utility of the EpiSwitch CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the PROWES StudyDOI 10.20944/preprints202508.0023.v1
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Semantic proximity
Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitorsSemantic proximity
A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors.Semantic proximity
Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity
Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity
Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumorsSemantic proximity
Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levelsSemantic proximity
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeSemantic proximity
Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indicationsSemantic proximity
Predicting Individual Responses in Phase I Oncology Trials Using Routinely Collected Clinical BiomarkersSemantic proximity
Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology TrialsSemantic proximity
Dynamic optimization of chemo–immunotherapy sequencing reveals phenotype-dependent regimens across tumor immune microenvironmentsSemantic proximity
Select a neighboring publication to make it the new centre.